Loading provider…
Loading provider…
Hematology & Oncology Physician in Santa Barbara, CA
NPI: 1295843738Primary Employer
Sansum Clinic Pueblo Multi-Specialty Clinic
sansumclinic.org
HQ Phone
Get M.D. Mukul's Phone Numberphone_androidMobile
Get M.D. Mukul's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2000 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University of Southern California/LAC+USC Medical Center
Fellowship • Medical Oncology
2003 - 2004
Fellowship • Hematology
2002 - 2003
Fellowship • Medical Oncology
2001 - 2002
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Internal Medicine
1998 - 2001
University of Zambia, School of Med
Medical School
Until 1994
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 361 | 875 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 138 | 232 |
| 3 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 117 | 581 |
| 4 | 96413Infusion of chemotherapy into a vein up to 1 hour | 106 | 593 |
| 5 | 96375Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 79 | 604 |
Authors: Manish Shah, Pooja Bhagia, Manish Shah, Albert Lockhart
Journal: Future Oncol
Publication Date: 2022-07-19
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 ...
Authors: Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter C. Enzinger, Judith Raimbourg
Authors: Manish Shah, Pooja Bhagia, Stella Kang, Manish Shah, Albert Lockhart
Journal: JAMA Oncol
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: M7824
Lead Sponsor: Ambrx, Inc.
Intervention / Treatment: DRUG: ARX788
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Canakinumab